Alnylam Pharmaceuticals, Inc.(ALNY)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ALNY | 30.87 B | 37.21x | 66.90% | 16.13% | $6.20 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
GILD | 194.07 B | - | 10.20% | -10.64% | -$2.82 | -20.68% | 2.23x | 2.05% | $160.51 | $111.27 |
VRTX | 130.44 B | 29.80x | 12.50% | 35.00% | $17.27 | 23.54% | 0.10x | 0.00% | $560.25 | $403.16 |
REGN | 81.67 B | 18.88x | 16.70% | 27.87% | $42.76 | 14.04% | 0.09x | 0.46% | $859.34 | $561.12 |
950220.KQ | 57.50 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Alnylam Pharmaceuticals, Inc. (ALNY) compared to its primary competitors (including GILD, VRTX, REGN) reveals distinct metrics. ALNY trades at a valuation premium compared to its competitors, with a P/E ratio of 37.2x versus the peer average of -2.3x (representing a -1738% premium). This indicates that the market expects superior growth or commands a quality premium for ALNY. In terms of growth, ALNY's revenue growth of 66.9% lags behind the peer average of 1149.7%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 16.1% compared to the peer average of 13.1%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ALNY ranks #3 in P/E ratio, #2 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $237.73 | $238.96 | $229.54 | $230.71 | 1,458,025 | -1.11% |
| 2026-10-19 | $232.65 | $236.54 | $231.26 | $233.29 | 1,344,100 | +0.63% |
| 2026-10-16 | $235.18 | $237.98 | $231.29 | $231.83 | 1,404,800 | -0.94% |
| 2026-10-15 | $230.00 | $234.30 | $228.12 | $234.03 | 1,257,400 | +4.26% |
| 2026-10-14 | $224.49 | $229.56 | $222.25 | $224.47 | 1,105,600 | +0.29% |
| 2026-10-13 | $228.93 | $229.53 | $221.56 | $223.82 | 1,119,000 | -1.41% |
| 2026-10-12 | $233.13 | $233.60 | $226.35 | $227.02 | 916,900 | -2.43% |
| 2026-10-09 | $224.74 | $232.94 | $222.71 | $232.68 | 959,400 | +3.63% |
| 2026-10-08 | $222.03 | $225.90 | $218.39 | $224.53 | 1,771,700 | +0.05% |
| 2026-10-07 | $224.39 | $230.42 | $222.46 | $224.41 | 1,064,100 | +0.21% |
| 2026-10-06 | $221.02 | $229.18 | $217.18 | $223.94 | 1,356,300 | +1.84% |
| 2026-10-05 | $218.36 | $222.08 | $215.46 | $219.89 | 1,281,100 | +0.08% |
| 2026-10-02 | $231.31 | $231.36 | $219.40 | $219.72 | 1,661,700 | -4.96% |
| 2026-10-01 | $248.21 | $251.71 | $230.06 | $231.18 | 2,017,300 | -6.31% |
| 2026-09-30 | $253.68 | $254.44 | $246.66 | $246.74 | 1,044,400 | -2.89% |
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.